Research programme: HIV infection therapeutics - RetroVirox

Drug Profile

Research programme: HIV infection therapeutics - RetroVirox

Latest Information Update: 14 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator RetroVirox
  • Class Small molecules
  • Mechanism of Action Immunomodulators; Virus internalisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research HIV infections

Most Recent Events

  • 14 Mar 2015 Early research is ongoing in USA
  • 12 Mar 2015 RetroVirox receives SBIR grant from NIAID for development of small molecule modulators in HIV infections
  • 11 Aug 2009 RetroVirox receives second SBIR grant from NIAID for development of viral entry inhibitors in HIV infections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top